Collection of Ph-negative progenitor cells from interferon-responsive patients with chronic myeloid leukemia: Effect of granulocyte-colony- stimulating factor mobilization

Haematologica

Volumn 85, Issue 6, 2000, Pages 647-652

  Olavarria, Eduardo ^a   Parker, Sally ^a   Craddock, Charles ^a   Philpott, Nicola ^a   Tiniakou, Maria ^a   Chase, Andrew ^a   Kanfer, Edward ^a   Apperley, Jane F ^a   Goldman, John M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Autografting; Chronic myeloid leukemia; Ph negative; Stem cells

Indexed keywords

BUSULFAN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; PREDNISOLONE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; LEUKAPHERESIS; LYMPHOCYTE COUNT; LYMPHOCYTE TRANSFORMATION; MALE; PHILADELPHIA 1 CHROMOSOME; TREATMENT OUTCOME;

ADULT; ANTIGENS, CD34; CELL COUNT; CYTOGENETICS; DISEASE-FREE SURVIVAL; FEMALE; GRAFT SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; INTERFERONS; LEUKAPHERESIS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE; MALE; MIDDLE AGED; PHILADELPHIA CHROMOSOME; STEM CELLS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0033923202     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. De Klein A, van Kessel AG, Grosveld G, et al. A cellular oncogene is translocated to the Philadelphia-chromosome in chronic myelocytic leukaemia. Nature 1982; 300:765-7.
2. Goldman JM, Szydlo R, Horowitz M, et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 1993; 82:2235-8.
3. Hochhaus A, Reiter A, Saussele S, et al. Molecular heterogeneity in complete cytogenetic responders after interferon alpha-therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 2000; 95:62-6.
4. Guilhot F, Chastang C, Michallet M, et al. Interferon alpha-2b combined with cytarabine versus Interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997; 24:223-9.
5. Simonsson B, Oberg G, Killander A et al. Intensive treatment in order to minimize the Ph-positive clone in chronic myelogenic leukaemia. Swedish CML Group. Bone Marrow Transplant 1994; 14(Suppl 3): S55-S56.
6. Kantarjian H, Talpaz M, Andersson B, et al. High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia. Bone Marrow Transplant 1994; 14:57-61.
7. Reiffers J, Goldman J, Meloni G, Cahn JY, Gratwohl A. Autologous stem cell transplantation in chronic myelogenous leukemia: a retrospective analysis of the European Group for Blood and Marrow Transplantation. Chronic Leukemia Working Party of the EBMT. Bone Marrow Transplant 1994; 14:407-10.
8. Olavarria E, Kanfer E, Szydlo R, et al. High-dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a single centre experience. Br J Haematol 2000; 108:769-77.
9. McGlave PB, De Fabritiis P, Deisseroth J, et al. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet 1994; 343:1486-8.
10. Deisseroth AB, Zu Z, Claxton D, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83:3068-76.
11. Carlo-Stella C, Mangoni L, Piovani G, et al. In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocytemacrophage colony-stimulating factor. Bone Marrow Transplant 1991; 8:265-73.
12. McGlave PB, Arthur D, Miller WJ, Lasky L, Kersey J. Autologous transplantation for CML using marrow treated ex vivo with recombinant human interferon gamma. Bone Marrow Transplant 1990; 6:115-20.
13. de Fabritiis P, Amadori S, Petti MC, et al. In vitro purging with BCR-ABL antisense oligodeoxynucleotides does not prevent haematologic reconstitution after autologous bone marrow transplantation. Leukemia 1995; 9:662-4.
14. Verfaillie CM, Bhatia R, Miller W, et al. BCR-ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early chronic phase but not accelerated phase chronic myelogenous leukemia patients. Blood 1996; 87:4770-9.
15. Barnett MJ, Eaves CJ, Phillips GL, et al. Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study. Blood 1994; 84:724-32.
16. Carella AM, Podestà M, Frassoni F, et al. Collection of "normal" blood populating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Bone Marrow Transplant 1993; 12:267-71.
17. Carella AM, Cunningham I, Lerma E, et al. Mobilization and transplantation of Philadelphia-negative peripheral blood progenitor cells early in chronic myelogenous leukemia. J Clin Oncol 1997; 15:1575-82.
18. Morton J, Mollee P, Taylor K, et al. Safe mobilization of normal progenitors in advanced chronic myeloid leukemia with intensive chemotherapy and granulocyte-colony stimulating factor. Leuk Res 1999; 23:177-83.
19. Chalmers EA, Franklin IM, Kelsey S, et al. Mobilization of Ph-negative peripheral blood stem cells in CML with idarubicin and cytarabine. Bone Marrow Transplant 1994; 14(Suppl 3):S38-41.
20. Carella AM, Lerma E, Corsetti MT, et al. Autografting with Philadelphia-chromosome negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Blood 1999; 83:1534-9.
21. Sheridan WP, Begley CG, To LB, et al. Phase II study of autologous filgrastim (G-CSF) mobilized peripheral blood progenitor cells to restore hemopoiesis after high dose chemotherapy for lymphoid malignancies. Bone Marrow Transplant 1994; 14:105-11.
22. Cleaver SA, Goldman JM. Use of G-CSF to mobilise PBSC in normal healthy donors: an international survey. Bone Marrow Transplant 1998; 21(Suppl 3):S29-31.
23. Karyotypic conversion by Interferon as preparative treatment for autologous BMT in Ph positive CML. [Italian Cooperative Study Group on Chronic Myeloid Leukaemia]. Leuk Lymphoma 1993; 11 (Suppl 1):277-80.
24. Archimbaud E, Michallet M, Philip I, et al. Granulocyte colony-stimulating factor given in addition to interferon-alpha to mobilize peripheral blood stem cells for autologous transplantation in chronic myeloid leukemia. Br J Haematol 1997; 99: 678-84.
25. Reiffers J, Taylor K, Gluckman E, et al. Collection of Ph-negative progenitor cells with granulocyte-colony stimulating factor in patients with chronic myeloid leukaemia who respond to recombinant alpha-interferon. Br J Haematol 1998; 102:639-46.
26. Giralt S, Escudier S, Kantarjian H, et al. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Eng J Med 1993; 329:757-61.
27. Richards SM. Interferon-alpha: results from randomized trials. Baillière's Clin Haem 1997; 10:307-18.
28. Talpaz M, Kantarjian H, Liang J, et al. Percentage of Philadelphia-chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells. Blood 1995; 85:3257-63.